

FIG. 1




FIG. 2




FIG. 3A

FIG. 3B




FIG. 4A

FIG. 4B

Ac-PRNK-ACC as an Optimized Tryptase Substrate (Tryptase v. Factor Xa v. Human thrombin)





FIG. 5

Fluorometric Tryptase Activity Assay Using Ac-PRNK-ACC in Spiked Assay Buffer






FIG. 7




FIG. 8

Effects on Ac-PRNK-ACC based Tryptase Activity Assay Exogenously Added Protease Inhibitors:




FIG. 9

Aprotonin Treated, Tryptase Standard Curves (Serum v. Buffer)




FIG. 10

Tryptase Quantitation in Urine (Aprotonin Treated v. Uninhibited Samples)




FIG. 11




FIG. 12

Enzymatic Inhibition of recombinant human β -II tryptase by PRNK-CMK




FIG. 13

Enzymatic Inhibition of Factor Xa by PRNK-CMK




FIG. 14